Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Charles Schwab Investment Management Inc. lowered its stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 13.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 72,093 shares of the company’s stock after selling 11,484 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.23% of Actinium Pharmaceuticals worth $136,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Marshall Wace LLP increased its holdings in shares of Actinium Pharmaceuticals by 67.9% during the 2nd quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after purchasing an additional 103,557 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $322,000. Bank of New York Mellon Corp increased its stake in Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares during the period. Creative Financial Designs Inc. ADV raised its holdings in Actinium Pharmaceuticals by 183.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock valued at $120,000 after acquiring an additional 41,250 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $356,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Down 3.4 %

Shares of NYSE:ATNM opened at $1.12 on Friday. The company has a fifty day moving average of $1.57. Actinium Pharmaceuticals, Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $10.24. The company has a market capitalization of $34.94 million, a PE ratio of -0.81 and a beta of 0.07.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).